Literature DB >> 34511734

Christian Bär1,2, Anselm A Derda1,3, Thomas Thum1,2,4.   

Abstract

COVID-19 still remains a severe global health threat. Despite the high-speed development of vaccines that efficiently prevent COVID-19, there are still no effective treatments of the disease once people are infected. MicroRNAs are powerful regulators of gene expression. They are intensely investigated as therapeutic targets up to the clinical stage. In addition, microRNAs can be detected in the circulation, and thus, represent promising diagnostic and prognostic biomarkers for (long)-COVID-19. © Die Autoren 2021.

Entities:  

Year:  2021        PMID: 34511734      PMCID: PMC8417673          DOI: 10.1007/s12268-021-1620-6

Source DB:  PubMed          Journal:  Biospektrum (Heidelb)        ISSN: 0947-0867


  9 in total

Review 1.  Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury.

Authors:  Janika Viereck; Thomas Thum
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

2.  Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?

Authors:  David de Gonzalo-Calvo; Angela Vea; Christian Bär; Jan Fiedler; Liam S Couch; Carlos Brotons; Vicenta Llorente-Cortes; Thomas Thum
Journal:  Eur Heart J       Date:  2019-05-21       Impact factor: 29.983

Review 3.  SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.

Authors:  Sonja Groß; Christopher Jahn; Sarah Cushman; Christian Bär; Thomas Thum
Journal:  J Mol Cell Cardiol       Date:  2020-04-30       Impact factor: 5.000

4.  Facing up to long COVID.

Authors: 
Journal:  Lancet       Date:  2020-12-12       Impact factor: 79.321

5.  Circulating cardiovascular microRNAs in critically ill COVID-19 patients.

Authors:  Ankita Garg; Benjamin Seeliger; Anselm A Derda; Sascha David; Christian Bär; Thomas Thum; Ke Xiao; Anika Gietz; Kristian Scherf; Kristina Sonnenschein; Isabell Pink; Marius M Hoeper; Tobias Welte; Johann Bauersachs
Journal:  Eur J Heart Fail       Date:  2021-03-05       Impact factor: 17.349

6.  MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes.

Authors:  Dongchao Lu; Shambhabi Chatterjee; Ke Xiao; Isabelle Riedel; Yibin Wang; Roger Foo; Christian Bär; Thomas Thum
Journal:  J Mol Cell Cardiol       Date:  2020-09-03       Impact factor: 5.000

7.  CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.

Authors:  Sandor Batkai; Celina Genschel; Janika Viereck; Steffen Rump; Christian Bär; Tobias Borchert; Denise Traxler; Martin Riesenhuber; Andreas Spannbauer; Dominika Lukovic; Katrin Zlabinger; Ena Hašimbegović; Johannes Winkler; Rita Garamvölgyi; Sonja Neitzel; Mariann Gyöngyösi; Thomas Thum
Journal:  Eur Heart J       Date:  2021-01-07       Impact factor: 29.983

8.  Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.

Authors:  Jörg Täubel; Wilfried Hauke; Steffen Rump; Janika Viereck; Sandor Batkai; Jenny Poetzsch; Laura Rode; Henning Weigt; Celina Genschel; Ulrike Lorch; Carmen Theek; Arthur A Levin; Johann Bauersachs; Scott D Solomon; Thomas Thum
Journal:  Eur Heart J       Date:  2021-01-07       Impact factor: 29.983

9.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).

Authors:  Valentina O Puntmann; M Ludovica Carerj; Imke Wieters; Masia Fahim; Christophe Arendt; Jedrzej Hoffmann; Anastasia Shchendrygina; Felicitas Escher; Mariuca Vasa-Nicotera; Andreas M Zeiher; Maria Vehreschild; Eike Nagel
Journal:  JAMA Cardiol       Date:  2020-11-01       Impact factor: 14.676

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.